Cargando…

Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma

BACKGROUND: RAD54L is a prominent member of the SWI2/SNF2 protein family, primarily involved in the homologous recombination repair (HRR) process, thereby playing a pivotal role in the repair of DNA double-strand breaks (DSBs). RAD54L has been implicated in the development of numerous tumors. Conseq...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yongzhen, Qiu, Chenjie, Fu, Qingsheng, Li, Tao, Zhang, Xudong, Zhu, Chunfu, Qin, Xihu, Wu, Baoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503553/
https://www.ncbi.nlm.nih.gov/pubmed/37719938
http://dx.doi.org/10.2147/JIR.S426558
_version_ 1785106545626841088
author Zhou, Yongzhen
Qiu, Chenjie
Fu, Qingsheng
Li, Tao
Zhang, Xudong
Zhu, Chunfu
Qin, Xihu
Wu, Baoqiang
author_facet Zhou, Yongzhen
Qiu, Chenjie
Fu, Qingsheng
Li, Tao
Zhang, Xudong
Zhu, Chunfu
Qin, Xihu
Wu, Baoqiang
author_sort Zhou, Yongzhen
collection PubMed
description BACKGROUND: RAD54L is a prominent member of the SWI2/SNF2 protein family, primarily involved in the homologous recombination repair (HRR) process, thereby playing a pivotal role in the repair of DNA double-strand breaks (DSBs). RAD54L has been implicated in the development of numerous tumors. Consequently, we aimed to investigate the potential contribution of RAD54L in pan-cancer. METHODS: Various databases and analytical tools were employed for bioinformatics analysis. Moreover, in vitro experiments were conducted to corroborate the findings from the bioinformatics analysis and delve deeper into the role of RAD54L in hepatocellular carcinoma (HCC). RESULTS: RAD54L expression demonstrated a significant elevation in the majority of tumors, and its overexpression was strongly associated with unfavorable survival outcomes. RAD54L displayed robust correlations with the infiltration levels of various immune cells, including cancer associated fibroblasts (CAFs), endothelial cells, and myeloid-derived suppressor cells (MDSCs). Additionally, associations were observed between RAD54L and key factors such as tumor mutation burden (TMB), microsatellite instability (MSI), multiple immune checkpoints, and immune cell infiltration. Moreover, a close relationship was observed between RAD54L expression levels in HCC and clinicopathological characteristics, as well as immune cell infiltration. Experimental techniques including qRT-PCR, Western blotting, colony-forming, Cell Counting Kit-8 (CCK-8), wound-healing, and transwell assays were employed, which collectively demonstrated that RAD54L promoted the proliferation and migration of HCC cells. CONCLUSION: RAD54L exhibits robust expression in both pan-cancer and HCC, exerting a significant influence on the proliferation and migration of HCC cells. These findings highlight its potential as a promising biomarker for pan-cancer and a prospective target for immunotherapy.
format Online
Article
Text
id pubmed-10503553
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105035532023-09-16 Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma Zhou, Yongzhen Qiu, Chenjie Fu, Qingsheng Li, Tao Zhang, Xudong Zhu, Chunfu Qin, Xihu Wu, Baoqiang J Inflamm Res Original Research BACKGROUND: RAD54L is a prominent member of the SWI2/SNF2 protein family, primarily involved in the homologous recombination repair (HRR) process, thereby playing a pivotal role in the repair of DNA double-strand breaks (DSBs). RAD54L has been implicated in the development of numerous tumors. Consequently, we aimed to investigate the potential contribution of RAD54L in pan-cancer. METHODS: Various databases and analytical tools were employed for bioinformatics analysis. Moreover, in vitro experiments were conducted to corroborate the findings from the bioinformatics analysis and delve deeper into the role of RAD54L in hepatocellular carcinoma (HCC). RESULTS: RAD54L expression demonstrated a significant elevation in the majority of tumors, and its overexpression was strongly associated with unfavorable survival outcomes. RAD54L displayed robust correlations with the infiltration levels of various immune cells, including cancer associated fibroblasts (CAFs), endothelial cells, and myeloid-derived suppressor cells (MDSCs). Additionally, associations were observed between RAD54L and key factors such as tumor mutation burden (TMB), microsatellite instability (MSI), multiple immune checkpoints, and immune cell infiltration. Moreover, a close relationship was observed between RAD54L expression levels in HCC and clinicopathological characteristics, as well as immune cell infiltration. Experimental techniques including qRT-PCR, Western blotting, colony-forming, Cell Counting Kit-8 (CCK-8), wound-healing, and transwell assays were employed, which collectively demonstrated that RAD54L promoted the proliferation and migration of HCC cells. CONCLUSION: RAD54L exhibits robust expression in both pan-cancer and HCC, exerting a significant influence on the proliferation and migration of HCC cells. These findings highlight its potential as a promising biomarker for pan-cancer and a prospective target for immunotherapy. Dove 2023-09-11 /pmc/articles/PMC10503553/ /pubmed/37719938 http://dx.doi.org/10.2147/JIR.S426558 Text en © 2023 Zhou et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Yongzhen
Qiu, Chenjie
Fu, Qingsheng
Li, Tao
Zhang, Xudong
Zhu, Chunfu
Qin, Xihu
Wu, Baoqiang
Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma
title Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma
title_full Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma
title_fullStr Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma
title_full_unstemmed Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma
title_short Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma
title_sort pan-cancer analysis of oncogenic role of rad54l and experimental validation in hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503553/
https://www.ncbi.nlm.nih.gov/pubmed/37719938
http://dx.doi.org/10.2147/JIR.S426558
work_keys_str_mv AT zhouyongzhen pancanceranalysisofoncogenicroleofrad54landexperimentalvalidationinhepatocellularcarcinoma
AT qiuchenjie pancanceranalysisofoncogenicroleofrad54landexperimentalvalidationinhepatocellularcarcinoma
AT fuqingsheng pancanceranalysisofoncogenicroleofrad54landexperimentalvalidationinhepatocellularcarcinoma
AT litao pancanceranalysisofoncogenicroleofrad54landexperimentalvalidationinhepatocellularcarcinoma
AT zhangxudong pancanceranalysisofoncogenicroleofrad54landexperimentalvalidationinhepatocellularcarcinoma
AT zhuchunfu pancanceranalysisofoncogenicroleofrad54landexperimentalvalidationinhepatocellularcarcinoma
AT qinxihu pancanceranalysisofoncogenicroleofrad54landexperimentalvalidationinhepatocellularcarcinoma
AT wubaoqiang pancanceranalysisofoncogenicroleofrad54landexperimentalvalidationinhepatocellularcarcinoma